Avanos Medical, Inc.
Description
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
About
CEO
Mr. Michael C. Greiner CPA
Employees
3,771
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Devices
MIC code
XNYS
Address
5405 Windward Parkway, Alpharetta, GA 30004, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 28, 2025 | — | — | — | — |
| Jul 29, 2025 | — | — | — | — |
| Apr 30, 2025 | — | — | — | — |
| Feb 18, 2025 | 0.40 | — | — | — |
| Oct 30, 2024 | 0.35 | 0.36 | 0.01 | 2.86% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 3 |
| Average estimate | — | 0.32 | — | 1.67 |
| Low estimate | — | 0.28 | — | 1.60 |
| High estimate | — | 0.38 | — | 1.80 |
| Last year EPS | — | 0.19 | — | 1.32 |
[stock_revenue_estimate]
Growth estimates
Current qtr
23.960%
Next qtr. (Mar 2025)
70.170%
Current year
-4.350%
Next year (Dec 2025)
26.260%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 673.30M | 684.10M | 587.00M | 714.80M | 697.60M |
| Cost of revenue | 293.60M | 289.90M | 287.80M | 341.50M | 295.40M |
| Gross profit | 379.70M | 394.20M | 299.20M | 373.30M | 402.20M |
| Operating expense | |||||
| Research & development | 27.20M | 29.20M | 30.60M | 34.90M | 37.70M |
| Selling general and admin | 335.00M | 326.50M | 285.30M | 332.60M | 399.10M |
| Other operating expenses | 13.30M | 3.00M | 22.30M | 51.90M | 21.10M |
| Operating income | 4.20M | 35.50M | -39.00M | -46.10M | -55.70M |
| Non operating interest income | |||||
| Income | 2.90M | 1.20M | 200,000 | 1.20M | 6.70M |
| Expense | 15.00M | 10.00M | 3.30M | 15.60M | 15.00M |
| Other income expense | — | — | — | — | — |
| Pretax income | -7.90M | 26.70M | -42.10M | -60.50M | -64.00M |
| Tax provision | 2.00M | 5.20M | -11.20M | -33.30M | -18.10M |
| Net income | -61.80M | 50.50M | 6.30M | -27.20M | -45.90M |
| Basic EPS | -1.32 | 1.08 | 0.11 | -0.57 | -0.96 |
| Diluted EPS | -1.32 | 1.07 | 0.11 | -0.57 | -0.96 |
| Basic average shares | 46.60M | 46.90M | 48.10M | 47.80M | 47.60M |
| Diluted average shares | 46.60M | 46.90M | 48.10M | 47.80M | 47.60M |
| EBITDA | 53.20M | 84.40M | -500,000 | -2.00M | -12.10M |
| Net income from continuing op. | -61.80M | 50.50M | 6.30M | -27.20M | -45.90M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.69B | 1.79B | 1.60B | 1.67B | 1.80B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 87.70M | 127.70M | 118.50M | 111.50M | 205.30M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 128.70M | 155.70M | 118.20M | 108.60M | 152.40M |
| Other receivables | — | — | — | — | — |
| Inventory | 163.20M | 132.30M | 159.30M | 168.90M | 145.90M |
| Prepaid assets | — | — | 18.60M | 18.90M | 23.50M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | 64.50M | 182.30M | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 28.80M | 13.90M | 18.60M | 18.90M | 23.50M |
| Non current assets | |||||
| Properties | 26.80M | 27.50M | 38.60M | 48.30M | 64.00M |
| Land and improvements | 1.30M | 1.10M | 1.10M | 1.10M | 1.00M |
| Machinery furniture equipment | 182.80M | 168.70M | 223.20M | 218.20M | 215.00M |
| Construction in progress | 18.00M | 16.40M | 32.00M | 23.30M | 18.90M |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -122.90M | -104.80M | -136.20M | -114.10M | -98.70M |
| Goodwill | 1.83B | 1.75B | 1.74B | 1.76B | 1.79B |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 239.50M | 234.20M | 141.20M | 157.70M | 184.30M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 25.80M | 22.20M | 26.50M | 21.80M | 27.40M |
| Total liabilities | 456.10M | 495.70M | 333.00M | 416.30M | 534.40M |
| Current liabilities | |||||
| Accounts payable | 56.30M | 67.90M | 56.40M | 67.60M | 83.00M |
| Accrued expenses | 76.50M | 76.60M | 65.10M | 80.50M | 111.60M |
| Short term debt | 21.40M | 18.20M | 14.70M | 15.50M | 14.70M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | 16.70M | 21.20M | 3.00M | 2.70M | 3.20M |
| Pensions | — | — | — | — | — |
| Other current liabilities | 63.70M | 7.10M | — | — | — |
| Non current liabilities | |||||
| Long term debt | 187.70M | 258.80M | 172.80M | 233.30M | 310.70M |
| Provision for risks and charges | — | — | — | 400,000 | 400,000 |
| Deferred liabilities | 23.80M | 25.40M | 11.90M | 5.70M | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 4.10M | 15.70M | 4.70M | 4.80M | 5.40M |
| Shareholders equity | |||||
| Common stock | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 |
| Retained earnings | -314.90M | -253.10M | -303.60M | -315.50M | -288.30M |
| Other shareholders equity | -27.00M | -35.80M | -33.80M | -28.10M | -32.00M |
| Total shareholders equity | 1.24B | 1.29B | 1.27B | 1.26B | 1.27B |
| Additional paid in capital | 1.66B | 1.65B | 1.63B | 1.61B | 1.59B |
| Treasury stock | 85.90M | 66.80M | 21.30M | 9.80M | 8.90M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Net Income | -61.80M | 50.50M | 6.30M | -27.20M | -45.90M | 57.50M | 79.30M | 39.80M | -426.30M | 27.10M | 154.60M | 152.60M | 142.40M |
| Depreciation | 46.10M | 47.70M | 38.30M | 42.90M | 36.90M | 33.50M | 59.50M | 65.20M | 65.40M | 85.40M | 69.20M | 57.60M | 51.10M |
| Deferred Taxes | — | — | -3.40M | 13.80M | -17.00M | -6.80M | -6.20M | -26.30M | -5.90M | -35.00M | -900,000 | -11.60M | 3.50M |
| Stock-Based Compensation | 15.80M | 15.90M | 13.20M | 12.10M | 10.50M | 10.50M | 12.60M | 14.80M | 14.10M | 7.90M | 6.00M | 5.30M | 2.60M |
| Other Non-Cash Items | — | — | — | — | — | — | — | -26.30M | 474.00M | -1.70M | 900,000 | 100,000 | 1.30M |
| Accounts Receivable | 39.00M | -24.70M | -10.80M | 45.80M | -800,000 | 67.40M | -15.30M | 8.40M | 9.00M | 15.10M | -19.50M | 26.40M | -20.00M |
| Accounts Payable | -14.40M | 35.40M | -11.90M | -18.90M | -83.60M | -64.00M | 18.80M | 6.50M | 14.70M | 4.50M | 15.10M | 8.00M | -7.60M |
| Other Assets & Liabilities | 4.70M | -30.90M | 15.70M | -21.80M | -21.30M | -34.50M | -16.80M | 41.00M | -20.20M | -2.90M | 14.30M | -15.10M | -13.10M |
| Operating Cash Flow | 29.40M | 93.90M | 47.40M | 46.70M | -121.20M | 63.60M | 131.90M | 123.10M | 124.80M | 100.40M | 239.70M | 223.30M | 160.20M |
| Investing Activities | |||||||||||||
| Capital Expenditures | — | — | — | — | — | — | 100,000 | 3.20M | 7.80M | 7.80M | 300,000 | 500,000 | 3.90M |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | 39.40M | -116.10M | — | -4.00M | — | 688.60M | — | -175.00M | — | — | -2.20M | — | -3.70M |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | -2.20M | — | — |
| Sale of Investments | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | 39.40M | -116.10M | — | -4.00M | -57.50M | 688.60M | 100,000 | -171.80M | 7.80M | 15.60M | -4.10M | 500,000 | 200,000 |
| Financing Activities | |||||||||||||
| Long-Term Debt Issuance | 55.00M | 400.00M | 20.00M | 185.00M | — | — | — | 72.00M | — | 638.00M | 4.00M | 7.10M | 53.20M |
| Long-Term Debt Payments | -119.70M | -296.60M | -70.00M | -254.80M | -200,000 | -339.00M | — | -72.00M | -51.00M | -13.80M | -67.90M | -31.20M | -41.40M |
| Other Financing Charges | -11.70M | -2.90M | — | -2.70M | — | -1.60M | — | -900,000 | 1.40M | 85.00M | -116.10M | -109.80M | -126.90M |
| Financing Cash Flow | -95.50M | 55.00M | -111.50M | 106.60M | -3.80M | -341.50M | -2.50M | -1.80M | -50.60M | 29.20M | -243.90M | -133.90M | -115.10M |
| Other Cash Details | |||||||||||||
| End Cash Position | 87.70M | 127.70M | 118.50M | 111.50M | 205.30M | 384.50M | 219.70M | 113.70M | 129.50M | 149.00M | 44.10M | 47.90M | 20.10M |
| Income Tax Paid | 23.60M | — | — | — | 8.40M | 96.60M | 21.40M | 29.10M | -43.30M | 87.60M | 74.20M | 94.30M | — |
| Interest Paid | 14.70M | 8.10M | 3.00M | 16.80M | 16.70M | 20.60M | 28.70M | 29.90M | -32.60M | — | — | — | — |
| Free Cash Flow | 14.60M | 71.60M | 66.30M | -22.70M | -125.10M | -194.70M | 101.00M | 159.70M | 27.20M | 69.40M | 174.80M | 161.80M | 99.90M |
Error: Invalid format in Holders JSON file.
Article
Avanos Medical (AVNS) Soars 7.2%: Is Further Upside Left in the Stock?
Avanos Medical (AVNS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Jan 28, 2025
Article
Reasons to Hold Avanos Medical Stock in Your Portfolio Now
AVNS' strong product line and focus on R&D raise optimism about the stock.
Jan 23, 2025
Article
Avanos Medical, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ALPHARETTA, Ga. , Jan. 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will present at the 43rd Annual J.P.
Jan 6, 2025
